ledipasvir/sofosbuvir / Generic mfg. - LARVOL DELTA

Treatment Outcomes of HCV Genotype 1b with Ledipasvir/Sofosbuvir and the Role of Resistance-Associated Substitutions in Mongolia (APASL 2026) - No abstract available

Clinical • Hepatitis C

Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia (APASL 2026) - No abstract available

Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

The oral cholate challenge test detects early hepatic improvement with ledipasvir/sofosbuvir in liver transplant recipients and patients with advanced cirrhosis (EASL 2026) - No abstract available

Clinical • Metastases • Fibrosis • Hepatology • Immunology • Transplantation

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

MANAGEMENT OF PEDIATRIC HCV-INFECTED PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER RETROSPECTIVE ITALIAN STUDY (EBMT 2026) - "All patients received myeloablative conditioning, including total body irradiation–based regimens (n=13) or busulfan/treosulfan-based regimens (n=3); one patient received thiotepa, fludarabine, and cyclophosphamide. Cyclosporine, ATG, and ATLG were administered in 9, 4, and 6 patients, respectively; ex vivo and in vivo T-cell depletion was performed in 6 and 1 patients.HCV genotypes were 1 (n=7) and 2 (n=8). Five patients received pre-HCT treatment with lamivudine (n=2), ledipasvir/sofosbuvir(n=2), and ribavirin (n=1), while 9 patients were treated after HCT with sofosbuvir (n=2), ledipasvir/sofosbuvir (n=3), glecaprevir/pibrentasvir (n=3), and sofosbuvir/velpatasvir (n=1); three were never treated... Our data suggest that HCT can be safely performed in pediatric patients with active HCV infection, even in the setting of intensive immunosuppression including in vivo and ex vivo T-cell depletion. Pre-transplant HCV viral load and DAAs exposure did not negatively impact..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Leukemia • Pediatrics • Transplantation • Transplantation Associated Thrombotic Microangiopathy

Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study. (PubMed, Pediatr Nephrol) - "SOF/LDV was found to be effective in the treatment of HCV in children and adolescents with CKD on HD with SVR12 86.4%, with no serious adverse events recorded."

Journal • Observational data • Chronic Kidney Disease • Hepatitis C • Nephrology • Pediatrics • Renal Disease

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients. (PubMed, Hepatol Res) - "Retreatment with SOF/VEL + RBV, GLE/PIB for 12 weeks, or SOF/LDV achieved high SVR12 rates, indicating that effective viral eradication is feasible using currently available DAA regimens even after prior treatment failure."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. (PubMed, J Clin Oncol) - "HCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting."

Journal • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Inflammation • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: Long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention. (PubMed, J Clin Virol) - "Among individuals offered DAA treatment, acceptance and cure rate were high. In this setting, HCV infection likely contributed to mortality, and affected older adults and migrants, suggesting these groups might be priorities for future micro-elimination programmes."

Journal • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Generic vs brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children. (PubMed, World J Hepatol) - "The use of generic SOF/LED in HCV infected children is safe and effective. It is comparable to the brand form at a reduced price and represents an affordable and effective alternative."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

Virological and antifibrotic efficacy of antiviral treatment for hepatitis В+C in HIV-positive patients. (PubMed, Wiad Lek) - " In patients with HIV/HBV/HCV coinfection, interferon-free regimens that include two direct-acting antivirals, either alone or in combination with ribavirin, demonstrated 100 % virologic efficacy and the most beneficial effects on the liver reducing the degree of liver fibrosis."

Journal • Fibrosis • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Exploring stationary phase morphologies as pathways to greener and faster LC for analyzing sofosbuvir and ledipasvir. (PubMed, Sci Rep) - "The total analysis time did not exceed 3 min, achieving high accuracy and sensitivity while minimizing the use of hazardous solvents. It achieved a very good score on different green analytical chemistry assessment metrics; 0.7 on AGREE, 76 on MoGAPI, 80 on BAGI, and 73 on CACI."

Journal • Hepatitis C • Infectious Disease • Inflammation

Hepatitis C Treatment During Pregnancy: Time for a Practice Change. (PubMed, Am J Obstet Gynecol MFM) - "Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir currently have the most data available in pregnancy and should be included in conversations regarding HCV treatment in pregnancy. Multidisciplinary care between maternal-fetal medicine, infectious disease, and hepatology can help promote access to HCV treatment in pregnancy."

Journal • Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Obstetrics

Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study. (PubMed, Medicine (Baltimore)) - "Fixed doses of LDV/SOF and GLE/PIB are effective for treating HCV GT-1 and GT-2 infections. There were no significant differences between the 2 regimens in on-treatment FIB-4 changes upon reaching SVR 12."

Clinical • Journal • Observational data • Retrospective data • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Paraneoplastic Minimal Change Disease Revealing an Underlying High-Grade Neuroendocrine Carcinoma: A Case Report (KIDNEY WEEK 2025) - "Case Description A 68-year-old male with HIV in remission, Hepatitis C treated with Harvoni, hyperlipidemia, CAD, and CKD presented with hypertensive urgency and AKI...Urine toxicology was positive for cocaine, methadone, and opiates...Recognizing this distinction is crucial to its therapeutic implications: remission of nephrotic syndrome has been observed following successful treatment of the underlying condition. In this case, nephrotic syndrome with abnormal MLN and remission of HIV and hepatitis B raised concern for malignancy, prompting a lung mass biopsy that confirmed the diagnosis."

Case report • Clinical • Chronic Kidney Disease • Dyslipidemia • Endocrine Cancer • Glomerulonephritis • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Nephrology • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor

Management of HCV-Infection in Pediatric Patients Undergoing HCT: A Single-Center Experience (ASH 2024) - "Four patients received myeloablative conditioning consisting of TBI + etoposide and busulfan + cyclophosphamide + thiotepa for 3 and 1 patient, respectively. One patient received a reduced-intensity conditioning regimen consisting of fludarabine + cyclophosphamide...DAAs were started after discontinuation of immunosuppressive therapy, for 4/5 patients.The combination of drugs used was : glecaprevir + pibrentasvir (2 patients), sofosbuvir + velpatasvir and ledipasvir + sofosbuvir...Two patients developed CMV-reactivation and required pre-emptive therapy with valganciclovir...No data are currently available regarding the possibility of viral reactivation in patients receiving treatment before transplant. Larger studies are needed to assess the right timing of treatment based on clinical evaluations."

Clinical • Acute Lymphocytic Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Fibrosis • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Cirrhosis • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • T Cell Non-Hodgkin Lymphoma

From Indeterminate to Invasive: A Perisplenic Nodule Unveils Metastatic Melanoma of Unknown Primary Following Brain Metastases (ACG 2025) - "This case underscores the diagnostic challenges of indeterminate visceral lesions and highlights the need for early evaluation in high-risk anatomical sites.Case Description/ A 75-year-old male with history of hepatocellular carcinoma (HCC) post resection and cirrhosis from hepatitis C (treated with ledipasvir/sofosbuvir) presented with stroke-like symptoms...This case underscores the diagnostic complexity of MUP and illustrates how a slowly enlarging, hemorrhagic perisplenic lesion—initially considered benign or indeterminate —can precede aggressive metastatic spread. It highlights the importance of early biopsy of indeterminate visceral lesions with increased size or metastases."

Metastases • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Melanoma • Ophthalmology • Solid Tumor • SOX10

Hepatocellular Carcinoma With Suspected Gastric Involvement (ACG 2025) - "This case underscores the importance of considering gastric invasion in patients with large HCCs presenting with gastrointestinal symptoms.Case Description/ A 67-year-old male with history of HCV complicated by cirrhosis treated in 2016 with ledipasvir/sofosbuvir presented with progressively worsening nausea and abdominal pain for two weeks...The feculent appearing material was likely necrotic tumor contents that eroded into the stomach resulting in aspiration and the patient's death. Recent evidence has supported surgical resection as a possible next step and expedited management may be prudent to avoid complications of invasion from aggressive lesions.Figure: Triple phase CT Abdomen/Pelvis showing the large liver lesion in (a) axial and (b) coronal views."

Cardiovascular • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Solid Tumor

High Rate of HCV Reinfection and the Efficacy of Standard Regimens in Men Who Have Sex with Men Living with HIV. (PubMed, J Infect Chemother) - "Among the reinfection cases, two individuals without prior DAA treatment received sofosbuvir/ledipasvir for 12 weeks, while five with prior treatment received glecaprevir/pibrentasvir for 8 weeks. These findings support the need to reframe HCV as a recurrent sexually transmitted infection. To ensure sustainable control in high-risk populations, healthcare systems must evolve to allow HCV treatment to be accessible, affordable, and repeatable, as is the case with the management of other common STIs."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. (PubMed, Eur J Clin Microbiol Infect Dis) - "This study confirms the excellent efficacy and good tolerability of SOF-based regimens for the treatment of hepatitis C in children aged 5 to 17 years in real-life settings, supporting the inclusion of pediatric patients in national treatment policies."

Journal • Real-world evidence • Fatigue • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Pain • Pediatrics

Safety and efficacy of different therapeutic regimens in Egyptian adults with moderate COVID-19 infection (EVEREST): a real-world retrospective study. (PubMed, Sci Rep) - "Patients were divided into four treatment arms: standard care, sofosbuvir/daclatasvir (sovodak) plus ivermectin, sofosbuvir/ledipasvir (SOF/LED) plus hydroxychloroquine, and SOF/LED plus ivermectin...Our study reveals that most tested antiviral combinations effectively reduced hospitalization days and progressive CT scans. These regimens demonstrated efficacy in treating moderate COVID-19 to prevent disease progression and complications."

Journal • Real-world evidence • Retrospective data • Infectious Disease • Novel Coronavirus Disease

THE MAJORITY OF PATIENTS WITH HEPATITIS C NOT ACHIEVING SVR CAN BE SUCCESSFULLY RETREATED WITH FIRST-LINE REGIMENS: RESULTS: FROM A MULTIDISCIPLINARY TEAM APPROACH TO GUIDE TREATMENT DECISIONS (AASLD 2025) - "A total of 263 retreatments were given, 176 (66.9%) 1st line (103 glecaprevir/pibrentasvir, 28 sofosbuvir/velpatasvir, 20 grazoprevir/elbasvir, 18 sofosbuvir/ledipasvir, 7 others) and 87 (33.1%) 2nd line (76 sofosbuvir/velpatasvir/voxilaprevir, 11 others).98 (37.2%) had documented risk factors for reinfection. An MDT approach to treatment failure, combined with resistance testing where available, allows for the majority of patients to be retreated with 1st line DAA regimen, with comparable rates of SVR to those treated with 2nd line regimens."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

To treat or not to treat young children with hepatitis C?--real-life experience. (PubMed, Eur J Pediatr) - "This study confirms both the efficacy and tolerability of DAAs for the treatment of hepatitis C in children aged 3-6 years in a clinical setting. Qualification for treatment in this age group should be made individually on the basis of the child's ability and willingness to swallow medications."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Pain

CLINICAL OUTCOME OF HCV INFECTION IN CHILDREN: AN ANALYSIS BASED ON SIX CASES OF HCV INFECTED CHILDREN (AASLD 2025) - "Four patients received sofosbuvir and velpatasvir for 12 weeks, while the other two received ledipasvir and sofosbuvir for the same duration. This small, single-center clinical study confirms the need for early treatment of pediatric patients with HCV infection to prevent serious liver-related complications caused by long-term infection. There is an urgent need to establish an integrated pathway of screening, diagnostic, and treatment pathway for pediatric patients with HCV infection."

Clinical • Clinical data • Hepatitis C • Infectious Disease • Liver Cirrhosis • Pediatrics

DEVELOPMENT OF B-CELL LYMPHOMA AFTER TREATMENT OF HEPATITIS C WITH DIRECT-ACTING ANTIVIRAL AGENTS (AASLD 2025) - "Sofosbuvir-based HCV therapy was used in 81% of patients, including sofosbuvir-ribavirin and sofosbuvir-ledipasvir regimens...Most cases responded well to rituximab-based chemotherapy, composed of R-CHOP or similar chemotherapy regimens with complete lymphoma regression in 25% of patients, and partial lymphoma response in 41.7% of patients, and the rest of patients without fully reported responses. While direct-acting antiviral agents have provided significant benefit for patients with hepatitis C, such as prevention of liver cirrhosis and hepatocellular carcinoma, reports in recent years have described development of B-cell lymphoma after HCV clearance with direct-acting antiviral agents. Increased monitoring of patients for B-cell lymphoma following direct-acting antiviral agents treatment for HCV can allow for earlier diagnosis resulting in earlier initiation of treatment and improvement in patient outcomes."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Fibrosis • Gastroenterology • Hematological Malignancies • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor